Nuvation Bio Inc. · NYSE:NUVB
Nuvation Bio — Merger or Acquisition (March 2024)
14 slides from Nuvation Bio's merger presentation, Mar 25, 2024
Slide 1: Nuvation Bio's Acquisition of AnHeart Therapeutics
DRIVEN BY SCIENCE FOCUSED ON LIFE March 25, 2024 Nuvation Bio’s Acquisition of AnHeart Therapeutics Exhibit 99.2
Slide 2: Forward looking statements
Forward looking statements Certain statements included in this presentation (this “Presentation”) that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statemen
Slide 3: Acquisition will be transformational for Nuvation Bio and potentially for patients
Acquisition of AnHeart Therapeutics will be transformational for Nuvation Bio and potentially for patients Taletrectinib, which is currently completing two pivotal studies, is a next-generation, potentially best-in-class ROS1 inhibitor differentiated by response rate, duration, and tolerability Crea
Slide 4: Acquisition positions Nuvation Bio to potentially become a commercial stage company by the end of 2025
Acquisition of AnHeart Therapeutics positions Nuvation Bio to potentially become a commercial stage company by the end of 2025 Currently granted: Priority review of two NDAs for taletrectinib by China’s NMPA1; Breakthrough Therapy Designations from U.S. FDA and China’s NMPA2 Intends to commercialize
Slide 5: Transaction will significantly increase potential upside, diversify risk, and position company for future growth
Transaction will significantly increase potential upside, diversify risk, and position company for future growth Nuvation Bio to acquire all share capital of AnHeart Therapeutics Immediately following closing, the former shareholders of AnHeart will own ~33% and the current stockholders of Nuvation
Slide 6: Nuvation Bio's robust cash balance can support continued development of the combined pipeline
Nuvation Bio’s robust cash balance can support continued development of the combined pipeline without a need to finance in the near term Program Potential Indication(s) Current Stage of Development Anticipated Milestones & Recent Updates Program Potential Indication(s) Preclinical Phase 1 Phase 2 Pi
Slide 7: AnHeart Therapeutics was founded in 2018 in conjunction with the in-license of taletrectinib
AnHeart Therapeutics was founded in 2018 in conjunction with the in-license of taletrectinib ‘18 –’20 '21-’22 2023 2024 AnHeart founded in 2018 Initiated global pivotal Phase 2 study of taletrectinib (TRUST-II) Updated TRUST-I results reported at ELCC 2023 China’s NMPA acceptance of NDA for taletrec
Slide 8: Taletrectinib is a next-generation, potentially best-in-class ROS1 inhibitor
Taletrectinib is a next-generation, potentially best-in-class ROS1 inhibitor differentiated by response rate, duration, and tolerability Breakthrough Therapy Designations (U.S. and China)1 China 1L & 2L NDAs accepted and granted priority review2 Sizeable ROS1+ NSCLC commercial opportunity In-license
Slide 9: Taletrectinib studied in two pivotal registrational trials with over 300 patients
Taletrectinib has been studied in two pivotal registrational trials that have included >300 patients in total, with results supporting BTDs3 in U.S. & China Stage 2 (n=167) Stage 1 Dose selection (n=6) Taletrectinib 600 mg QD Taletrectinib 400 mg QD Cohort 2: Crizotinib-pretreated Taletrectinib 600
Slide 10: The ROS1-positive NSCLC market represents a sizeable commercial opportunity
The ROS1-positive NSCLC market represents a sizeable commercial opportunity 1. American Cancer Society (2024). 2. National Center for Biotechnology Information: Gendarme et al., Curr Oncol (2022). 3. Initially approved by U.S. FDA in 2011 for the treatment of patients with ALK-positive NSCLC; later
Slide 11: AnHeart acquisition will also add safusidenib to Nuvation Bio's pipeline
AnHeart acquisition will also add safusidenib to Nuvation Bio’s pipeline Global rights In-licensed from Daiichi Sankyo Daiichi Sankyo retains rights in Japan4 Validated target Positive Ph 3 data with vorasidenib1 in glioma presented at ASCO ‘232 Unmet need People diagnosed with glioma have no target
Slide 12: The low grade IDH1-mutant glioma market represents a sizeable commercial opportunity
The low grade IDH1-mutant glioma market represents a sizeable commercial opportunity Low grade IDH1-mutant glioma patients are in need of better treatment options ~13.3K – 18.3K people living with low grade IDH1-mutant glioma in the U.S. Grade 2: ~63% Grade 3 ~37% Source: CBTRUS Statistical Report:
Slide 13: Safusidenib clinical trial data set
Safusidenib clinical trial data set approaches 100 patients Japan Grade 2 IDH1-mutant glioma n=27 Japan Grades 2-4 IDH1-mutant glioma n=47 Global Grades 2-3 IDH1-mutant glioma Part 1: Dose evaluation (n=25) Part 2: Design under discussion J101 – Phase 1 G203 – Phase 2 J201 – Phase 2 Sponsor: Daiichi
Slide 14: Acquisition will be transformational for Nuvation Bio and potentially for patients
Acquisition of AnHeart Therapeutics will be transformational for Nuvation Bio and potentially for patients Taletrectinib, which is currently completing two pivotal studies, is a next-generation, potentially best-in-class ROS1 inhibitor differentiated by response rate, duration, and tolerability Crea